Epigenomics AG. a molecular diagnostics company developing tests based on DNA methylation, is presenting new clinical data on its colorectal cancer early detection marker in blood. The results indicate that, combined with a second proprietary marker, the test is also able to detect most polyps without many false positive results. Colon polyps are benign proliferations that can give rise to cancer. The risk is considerably high if they are greater than 1 cm in size. PrimeZone (http://www.primezone.com/newsroom/news.html?ref=nrdigest&vid=6290&topic=256&d=101662)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Motus GI’s Pure-Vu System Receives Chinese Patent
The device previously received 510(k) clearance from the FDA and CE Mark approval in Europe.
House Committee Approves Spending Bill to Raise FDA’s Budget
The Senate is expected to mark up its version of the bill this week.